Zevenbergen Capital Investments LLC increased its position in shares of Zoetis Inc. (NYSE:ZTS) by 4.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,427 shares of the company’s stock after acquiring an additional 365 shares during the period. Zevenbergen Capital Investments LLC’s holdings in Zoetis were worth $588,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. lifted its holdings in Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after acquiring an additional 230 shares during the last quarter. Guardian Life Insurance Co. of America boosted its position in shares of Zoetis by 0.7% during the 1st quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after purchasing an additional 13 shares in the last quarter. Almanack Investment Partners LLC. bought a new position in shares of Zoetis during the 2nd quarter valued at about $119,000. Assetmark Inc. boosted its position in shares of Zoetis by 4.6% during the 1st quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock valued at $102,000 after purchasing an additional 85 shares in the last quarter. Finally, Point72 Asia Hong Kong Ltd bought a new position in shares of Zoetis during the 1st quarter valued at about $111,000. 93.20% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts recently commented on the stock. BMO Capital Markets downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and boosted their target price for the stock from $64.00 to $65.00 in a report on Tuesday, June 13th. They noted that the move was a valuation call. Cowen and Company set a $70.00 target price on shares of Zoetis and gave the stock a “buy” rating in a report on Monday, July 17th. Cantor Fitzgerald set a $75.00 target price on shares of Zoetis and gave the stock a “buy” rating in a report on Monday, August 14th. Stifel Nicolaus restated a “buy” rating and set a $65.00 target price on shares of Zoetis in a report on Friday, July 21st. Finally, CL King assumed coverage on shares of Zoetis in a research report on Friday, May 26th. They issued a “buy” rating and a $71.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the company’s stock. Zoetis presently has a consensus rating of “Buy” and an average price target of $65.44.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/09/23/zoetis-inc-zts-shares-bought-by-zevenbergen-capital-investments-llc.html.

Shares of Zoetis Inc. (NYSE:ZTS) traded down 0.12% during midday trading on Friday, reaching $64.16. The company had a trading volume of 1,538,406 shares. The company’s 50-day moving average is $62.44 and its 200-day moving average is $59.64. The firm has a market cap of $31.38 billion, a P/E ratio of 36.27 and a beta of 1.02. Zoetis Inc. has a 52-week low of $46.86 and a 52-week high of $65.83.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.53. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The firm had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.27 billion. During the same period in the previous year, the firm earned $0.49 earnings per share. The company’s revenue was up 5.0% on a year-over-year basis. Equities research analysts expect that Zoetis Inc. will post $2.34 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.